En Es
Categories

Industry News

Global Lateral Flow Assay Market to Exceed 8 Billion by 2022

By Labmedica International staff writers
08 Sep 2017

Image: The global lateral flow assay market is projected to grow to USD 8.24 billion by 2022 (Photo courtesy of Alere).The global lateral flow assay market is projected to grow at a CAGR of 8.2% from USD 5.55 billion in 2017 to USD 8.24 billion by 2022, driven mainly by the high prevalence of infectious diseases worldwide, rapidly growing geriatric population, growing demand for point-of-care (POC) testing, and rising use of home-based lateral flow assay devices. These are the latest findings of Research and Markets, (Dublin, Ireland), a global market research company.

Based on product, the kits & reagents segment held the largest market share in 2016, due to the increasing application of lateral flow kits & reagents for POC testing, growing burden of chronic diseases, and increasing use of lateral flow kits in home care. On the basis of application, the clinical/POC testing segment accounted for the largest share of the market in 2016, led by rise in population levels and prevalence of chronic diseases, growing pressure to reduce healthcare costs, and increasing demand for patient-centric care. Based on end-user, the hospitals and clinics segment accounted for the largest share of the market in 2016, mainly due to technological advancements, increasing adoption of POC testing, innovative technologies and devices, and growing patient inclination toward fast and early diagnosis.

Geographically, North America held the largest market share in 2016, primarily due to the presence of its highly developed healthcare system, rising geriatric population, increasing incidence of chronic diseases, quick adoption of new innovative products, and a large number of lateral flow assay kits manufacturing companies in this region. However, reluctance among doctors and patients to change existing diagnostic procedures, implementation of excise duty by the US government, and stringent & time-consuming regulatory policies are restraining the growth of the lateral flow assay market.

Alere Inc. (Waltham, MA, USA) dominated the global lateral flow assay market in 2016 due to its diversified product portfolio of lateral flow assay kits and readers, as well as innovative contributions to the lateral flow assay market. Over the years, the company has developed innovative lateral flow assay products for various medical applications, such as POC testing products that make workflows more efficient and provide quality test results. The company has a strong manufacturing and distribution network across the globe, which allows it to serve customers across the Americas, Africa, Europe, the Middle East, and Asia-Pacific.



E-mail Print
FaceBook Twitter Google+ Linked in

Alere

Develops rapid point-of-care diagnostics that focus on infectious disease, cardiology, oncology, drugs of abuse, and women's health.
More info

Additional news

23 Feb 2018
AI Applications Predict Part Failures in Imaging Modalities
Machine data analytics company, Glassbeam, Inc. has built Artificial Intelligence (AI) applications powered by Machine Learning (ML) models for predicting part failures in expensive imaging modalities. The new applications delivered in real time through cloud-based dashboards and rules-based alerts are expected to change the way equipment maintenance is currently performed by in-house support staff at healthcare providers, independent service organizations (ISOs), and OEMs.
Read More
23 Feb 2018
Top Factors Driving Global POC Glucose Monitoring Devices Market
The global market for POC blood glucose monitoring devices is expected to grow at a CAGR of over 8% during the period 2018-2022, driven mainly by public and private initiatives to reduce diabetic cases. These are the latest findings of Technavio Research, a global technology research and advisory company.
Read More
21 Feb 2018
Stroke Detection Software Receives FDA Clearance
The US FDA has approved a new clinical decision support software that notifies neurologists about a potential stroke in their patients by analyzing computed tomography (CT) results. The tool named Contact has been developed by Viz.ai, a direct-to-intervention healthcare company that uses artificial intelligence (AI) and deep learning algorithms to analyze medical data and improve medical workflow.
Read More
21 Feb 2018
AI in Medical Imaging to Surge in Coming Years
The use of machine learning or artificial intelligence (AI) technology by hospitals and imaging centers is expected to surge by 2020, with its highest application to be in the area of breast imaging.
Read More
21 Feb 2018
New Deep Learning-Based Algorithm Can Assess Breast Density
Researchers from the University of Pittsburgh Medical Center have developed a new deep learning-based algorithm for breast density segmentation and estimation that correlated well with BI-RADS density assessments by radiologists and also outperformed an existing state-of-the-art algorithm.
Read More
13 Feb 2018
QIAGEN Enters into Agreement to Acquire STAT-Dx
QIAGEN N.V. has entered into an agreement to acquire STAT-Dx, a privately-held company which develops next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven QIAGEN chemistries.
Read More
08 Feb 2018
AI Could Learn How to Understand Radiologist Reports
Researchers at the Icahn School of Medicine at Mount Sinai have used machine learning techniques, including natural language processing algorithms, to identify clinical concepts in radiologist reports for computed tomography (CT) scans. The technology marks an important first step in the development of artificial intelligence (AI) that could interpret scans and diagnose conditions.
Read More
08 Feb 2018
AR and VR in Healthcare Market to Reach USD 4.9 Million by 2023
The augmented reality (AR) and virtual reality (VR) in the healthcare market was valued at USD 769.2 million in 2017 and is expected to grow at a CAGR of 36.6% during the forecast period to reach USD 4,997.9 million by 2023. The market growth will be driven by increasing penetration of connected devices in the healthcare sector, rising investment in healthcare AR and VR, and growing need to reduce healthcare costs. However, the lack of competence in the deployment of AR and VR solutions, and lack of expertise among medical practitioners to adopt new technologies are the major restraints for market growth.
Read More
08 Feb 2018
Elekta Collaborates with IBM Watson Health to Bring AI to Oncology
Elekta is collaborating with IBM Watson Health to offer Watson for Oncology with its cancer care solutions. Beginning in early 2018, Elekta will sell Watson for Oncology as a clinical decision support solution, paired within its digital cancer care solutions, including the MOSAIQ Oncology Information System.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions